Browse by author
Lookup NU author(s): Professor Simon BaileyORCiD
Full text for this publication is not currently held within this repository. Alternative links are provided below where available.
Purpose: To evaluate carboplatin, etoposide, and bleomycin (JEB) in children with malignant extracranial germ cell tumors (GCTs). Patients and Methods: Malignant GCTs in children aged 0 to 16, years were excised without major morbidity or otherwise biopsied. Stage I testicular and some ovarian GCTs were resected and monitored with alpha-fetoprotein (AFP) ("watch-and-wait" approach). Patients with recurrent stage I disease and all other patients received JEB (etoposide 120 mg/m(2) on days 1 through 3, carboplatin 600 mg/m(2) on day 2, and bleomycin 15 mg/m(2) on day 3), Courses were administered every 3 to 4 weeks until remission, and then two more courses were given. Chemotherapy toxicities were assessed using World Health Organization or Brock grading. Results: Between January 1989 and December 1997; 192 patients were registered. Eight were excluded because either there wets no histologic diagnosis (n = 3) or chemotherapy was given off-study (n = 5), The remaining 184 patients had germinoma In = 20), malignant teratoma In = 55), embryonal carcinoma (n = 1), yolk sac tumor (n = 107), or choriocarcinoma In = 1). forty-seven patients were treated with surgery alone, and 137 patients received JEB. The 5-year survival rate in March 1999 for all 184 patients was 93.2% (95% confidence interval [CI], 87.9% to 96,3%): for the 137 JEB-treated patients, it was 90.9% (95% CI, 83.9% to 95.0%), with an event-free survival rate of 87.8% (95% CI, 81.1% to 92,4%). The median follow-up after JEB treatment wets 53 months (range, 0 to 109 months): the median number of courses wets five (range, three to eight). Site, stage, and AFP level had prognostic significance. Nonfatal hematologic toxicity was common, but deafness and pulmonary and renal toxicities were rare. One child died of a thoracic tumor and bronchopulmonary dysplasia, and another died of acute myeloid leukemia. Conclusion: Conservative surgery, a watch-and-wait approach after complete excision, and JEB for those requiring chemotherapy produced high cure rates and few serious complications. (C) 2000 by American Society of Clinical Oncology.
Author(s): Mann, J. R., Raafat, F., Robinson, K., Imeson, J., Gornall, P., Sokal, M., Gray, E., McKeever, P., Hale, J., Bailey, S., Oakhill, A.
Publication type: Article
Publication status: Published
Journal: Journal of Clinical Oncology
Year: 2000
Volume: 18
Issue: 22
Pages: 3809-3818
ISSN (print): 0732-183X
ISSN (electronic): 1527-7755
URL: http://jco.ascopubs.org/cgi/content/abstract/18/22/3809
PubMed id: 11078494
